Slide 1: Cingulate Therapeutics
Cingulate Therapeutics Developing next-generation drug candidates where standard-of- care treatments result in suboptimal outcomes May 2022 4 an CING-US-107-0523
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than stat
Slide 3: Cingulate Mission
Cingulate Mission Cingulate will develop, shape market acceptance, and prepare to commercialize next- generation drug candidates in markets where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value P
Slide 4: Targeting Treatment of ADHD - $18Bn US Market Opportunity
Targeting Treatment of ADHD - $18Bn US Market Opportunity Frequently diagnosed, chronic pattern interfering with functioning / development ~17 Million US ADHD Societal Impact of ADHD Patients Estimated annual incremental costs of $143 to $266 billion in the United States Adult ADHD Children & Adoles
Slide 5: $18 Billion US ADHD Market Dominated by Stimulants
$18 Billion US ADHD Market Dominated by Stimulants aff B ‘ fs 3 F Million Prescriptions par'Yea Despite multitude of options, patients needs are still not being met even by the most widely prescribed extended- Methylphenidates Amphetamines pat release ADHD medications = Ritalin® / LA = Vyvanse® = Co
Slide 6: ADHD Market Currently Dominated by Stimulant Products
ADHD Market Currently Dominated by 4 Stimulant Products Major Unmet Medical Needs Persist ADHD 1 4 BRANDS APPROVED ATTRIBUTES UNMET NEEDS Fast Onset of Duration Action Entire Active- Minimize (less onset) < 30 min Day Efficacy* Crash/Rebound Data Not Vyvanse® 2007 2 hours 12 hours x x Available y Ad
Slide 7: ADHD Market Leaders Do Not Provide "Built-In Booster"
ADHD Market Leaders Do Not Provide “Built-In Booster” Market Leaders Stop Delivery of Medication 4-5 Hours After Administration ADHD Al 41 BRANDS ATTRIBUTES RELEASE PROFILES Duration (less onset) DOSE 1 / STYLE / TIME DOSE 2 / STYLE / TIME 100% PRODRUG Vyvanse® 2 hours 12 hours SUSTAINED RELEASE (0)
Slide 8: Recent Launches Lack Meaningful Clinical Innovation
Recent Launches Lack Meaningful Clinical Innovation Niche Delivery Platforms — Designed to Fail in ADHD ADHD BRANDS ATTRIBUTES" UNMET NEEDS Fast Acting Entire Active- Avoid Product Onset Duration (< 30 min) Day Efficacy* Crash/Rebound Quillivant / Chew® XR 60 mins 8 hours x x x x Mydayis® 2or4 hrs 1
Slide 9: The Cingulate Solution for ADHD Patients & Providers
The Cingulate Solution for ADHD Patients & Providers 2 SESMASTERY” Y8ACCOMPLISH® CTx-1301 CTx-1302 CING-US-107-0523
Slide 10: Cingulate's Precision Timed Release Platform Technology
Cingulate’s Precision Timed Release™ Platform Technology Disruptive Technology Changing the Paradigm of Oral Drug Delivery * Our current pipeline candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form, smaller than many single dose ADHD produ
Slide 11: Nine Significant Points of Differentiation
Nine Significant Points of Differentiation NO ADHD product available today combines all unmet needs PTR technology affords our product candidates the following potential advantages over currently available ADHD treatments , ae Seeve ey eae gl Reduce abuse / diversion by eliminating booster v Fast on
Slide 12: CTx-1301 (d-MPH) and CTx-1302 (d-AMP)
CTx-1301 (d-MPH) and CTx-1302 (d-AMP) TARGET RIBUTES RELEASE PROFILES CTx-1301 . Up to 16 i 45% SUSTAINED RELEASE OVER 90 20% IMMEDIATE (d-MPH) sult hours See eo us anaes MINUTES AT HOUR 3 RELEASE AT HOUR 7 CTx-1302 i Up to 16 — 35% SUSTAINED RELEASE OVER 90 20% IMMEDIATE (d-AMP) $0 mins hours S25 I
Slide 13: CTx-1301 Clinical Phase Study Results
CTx-1301 Clinical Phase 2 Study Results Plasma dexmethylphenidate (AMPH) Concentration vs Time Extends duration for ‘entire active-day’ without Low Dose the booster dose! 3000 Results demonstrate fast onset with the desired Fast Onset controlled descent 2500 | ; Minimize ‘crash/rebound’ effect, comm
Slide 14: At the Individual Level, Tri-modal Delivery is Clear
At the Individual Level, Tri-modal Delivery is Clear Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate the Booster Dose Subject ID: 01-510 Subject ID: 01-504 —— CTx-1301 6.25-mg —e— Focalin XR 5-mg 25000 2 20000 —— CTx-1301 50-mg 15000 —®— Focalin XR 40-mg ° s 10 1s 20 2s 30 CINGULATE"
Slide 15: CTx-1301 Demonstrated Significantly Lower Adverse Events
CTx-1301 Demonstrated Significantly Lower Adverse Events 28.6% reduction in TEAE's related to CTx-1301 versus Focalin XR (14.3% difference) Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5 mg 6.25 mg 40 mg 50mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Treatment Emergent Adverse
Slide 16: Planned Phase Trials
if © : “ESMASTERY Planned Phase 3 Trials 4 2019 - 2021 2022 Phase 1 & 2 Food Formulation Comparative Effect Study BA Study eae n= Pediatric / Pediatric Phase 3 Adolescent Efficacy & Fixed-Dose, Safety Placebo- Onset / Controlled Trial Duration n=300 n~50 ( Dose-Optimization Extension (6-17 y/o) ( Ex
Slide 17: Commercialization to Drive Revenue
Commercialization to Drive Revenue Changing dynamics in ADHD Maximize Access for Patients and Providers commercial landscape * — Efficacy, tolerability, 1 vs 2 Rx’s, Abuse/Diversion * — Ability to dominate share of voice + REBATES o Concerta, Adderall XR, Focalin XR are all ‘ PBM's driven by rebate
Slide 18: Exclusivity: IP, Agreements, and Trade Secrets
Exclusivity: IP, Agreements, and Trade Secrets Intellectual property rights expected to provide exclusivity through 2035 at a minimum ° OralogiK™ Erosion Barrier Layer + Five (5) patents granted (US & Global) expiry dates ranging from 2031 to 2035, ay * One (1) OralogiK™ patent pending (US, Europe)
Slide 19: Vast Pipeline of Next-Generation Medications Beyond ADHD
Vast Pipeline of Next-Generation Medications Beyond ADHD v Leverage our PTR platform in other therapeutics areas Y Market Criteria: © $1Bn+ in peak sales © Next-generation mediations with significant improvement over existing therapies Identified PTR™ Platform Pipeline Opportunities Near-Term Focus
Slide 20: Cingulate Mission
Cingulate Mission Develop... Shape market acceptance, and... Prepare to commercialize next-generation drug candidates... Where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value ° Cingulate CINGULAT
Slide 21: Appendix
Slide 22: Senior Management Team
Senior Management Team Proven, Experienced Pharmaceutical Industry Team Leadership team brings extensive expertise in ADHD, clinical trials, pharmaceutical development, manufacturing, commercialization, market access, and patient care. Team has led 200+ clinical trials, 300+ publications, 30+ FDA dr
Slide 23: Board of Directors
co C INGULATE- Board of Directors Experienced and Accomplished Directors Shane J Schaffer, PharmD Peter J Werth Chairman & Chief Executive Officer @Pfizer tb NOVARTIS SANOFI\Y HER ERTE r Jeff Conroy Gregg Givens eEMBEDY 4 pwe olslr (MASTER COMPLEXITY Patrick Gallagher, MBA CFA LAIDLAW COMPANY Jeff H
Slide 24: 100% of Stimulants Have Been Approved
100% of Stimulants Have Been Approved 30 stimulant product approvals in ADHD over last 50+ years Azstarys* APPROVED March 2021 Evekeo ODT* ‘APPROVED January 2019 Adhansia XR* APPROVED February 2019 Evekeo APPROVED August 2018 Jornay PM* APPROVED August 2018 Adzenys ER* APPROVED. September 2017 Cotem